566
Participants
Start Date
March 1, 2023
Primary Completion Date
January 1, 2027
Study Completion Date
January 1, 2029
APA + ADT
"All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment."
Local Treatmetn RT or RP
"Patients who will undergo radiotherapy as a local treatment must be treated according to the following scheme:~External beam radiotherapy administered at 36 Gy in six consecutive weekly fractions of 6 Gy, or 55 Gy in 20 daily fractions of 2・75 Gy over 4 weeks.~Radiation therapy will be given with the patient supine and with a full bladder and an empty rectum. The planned target volume is prostate only, with an 8 mm margin posteriorly and a 10 mm margin elsewhere.~No RT on lymph nodes is foreseen. RT should begin 6 months after the first dose of apalutamide (+/- 2 weeks).~Radical prostatectomy should be performed 6 months after the first dose of apalutamide (+/- 2 weeks)."
NOT_YET_RECRUITING
European Institute of Oncology, Milan
NOT_YET_RECRUITING
ASST Santi Paolo e Carlo, Milan
RECRUITING
Istituto Tumori Milano, Milan
ASST Santi Paolo e Carlo
OTHER
European Institute of Oncology
OTHER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER